Tucson, Arizona / April 14, 2026 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced that it will present new data at the American Thoracic Society Respiratory Innovation Summit (RIS), taking place May 15 to 16, 2026 in Orlando, Florida.
The poster highlights a key step forward in the development of Aspiro’s inhaled program. Recent work has resulted in a stable aerosol formulation that enables consistent, reproducible delivery to the lung. These findings support the feasibility of inhaled delivery for therapies designed to engage the underlying biology of respiratory disease.
“Achieving consistent and reproducible delivery to the lung is a critical step for any inhaled therapeutic,” said James Lovgren, Chief Executive Officer of Aspiro Therapeutics. “This progress supports our approach to directly target the biology of disease and reinforces the potential of our platform.”
Aspiro’s approach is focused on moving beyond symptom management and toward therapies that can change the course of disease in conditions such as COPD and asthma. By combining targeted delivery with a mechanism designed to modulate disease biology, the program aims to address key limitations of current treatment options.
The Respiratory Innovation Summit brings together leaders across biopharma, investment, and clinical research to discuss emerging approaches in respiratory medicine. Aspiro looks forward to engaging with partners and stakeholders during the meeting.
Aspiro Therapeutics acknowledges the support of the Flinn Foundation in advancing this work.
